Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03641313
Title Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma


Berzosertib + Irinotecan

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST